Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

摘要

The phase 1-2 study CO-338-010 (Study 10; NCT0I4827I5) is evaluating single-agent rucaparib, a poly(ADP-ribose) polymerase inhibitor, administered orally to patients with an advanced solid tumor. In the dose escalation phase (Part I), we characterized the single-dose and steady-state pharmacokinetic profiles of rucaparib administered once daily (QD; dose range, 40-500 mg; n = 16) or twice daily (BID; dose range, 240-840 mg; n = 30). Across all dosing schedules examined, the plasma exposure of rucaparib was approximately dose proportional; half-life was approximately 17 hours, and median time to maximum concentration (t_(max)) ranged from 1.5 to 6.0 hours after a single dose and 1.5 to 4.0 hours following repeated dosing. The steady-state accumulation ratio ranged from 1.60 to 2.33 following QD dosing and 1.47 to 5.44 following BID dosing. No effect of food on rucaparib pharmacokinetics was observed with a single dose of 40 mg (n = 3) or 300 mg (n = 6). In a phase 2 portion of the study (Part 3), the pharmacokinetic profile of rucaparib was further evaluated at the recommended phase 2 dose of 600 mg BID (n = 26). The mean (coefficient of variation) steady-state maximum concentration (C_(max)) and area under the concentration-time curve from time zero to 12 hours (AUC_(0-12h)) were 1940 ng/mL (54%) and 16 900 ng · h/mL (54%), respectively. A high-fat meal moderately increased rucaparib exposure. The fed-to-fasted geometric mean ratios (90% confidence interval [Cl]) for AUC_(0-24h) and C_(max) were 138% (117%-162%) and 120% (99.1%-146%); the median (90%CI) t_(max) delay was 2.5 (0.5-4.4) hours.